KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for TherapeuticsMD (TXMD) over the last 4 years, with Dec 2024 value amounting to -$0.20.

  • TherapeuticsMD's EPS (Weighted Average and Diluted) rose 120.00% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.01, marking a year-over-year increase of 103.57%. This contributed to the annual value of -$0.20 for FY2024, which is 79.80% up from last year.
  • Per TherapeuticsMD's latest filing, its EPS (Weighted Average and Diluted) stood at -$0.20 for FY2024, which was up 79.80% from -$0.99 recorded in FY2023.
  • TherapeuticsMD's 5-year EPS (Weighted Average and Diluted) high stood at $11.96 for FY2022, and its period low was -$21.66 during FY2021.
  • In the last 3 years, TherapeuticsMD's EPS (Weighted Average and Diluted) had a median value of -$0.20 in 2024 and averaged $3.59.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 155.22% in 2022, then crashed by 108.28% in 2023.
  • TherapeuticsMD's EPS (Weighted Average and Diluted) (Yearly) stood at -$21.66 in 2021, then skyrocketed by 155.22% to $11.96 in 2022, then slumped by 108.28% to -$0.99 in 2023, then soared by 79.80% to -$0.20 in 2024.